Morgan Stanley Still Sees Acceleration Risk for C.R. Bard

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Underweight rating and $120.00 price target on

. In the report, Morgan Stanley noted, “Our less constructive view on Bard hinges on two ideas: (i) We believe investments will take longer and generate lower returns. (ii) Consensus expectations around Lutonix are simply too enthusiastic. Despite recent confirmatory data points, the stock does not reflect this. We remain Underweight.” C.R. Bard closed on Tuesday at $141.11.